A coronavirus vaccine trial in the United State, US, has given a dose to
its first participant. The study aims to enroll a total of 45 healthy
adults over a six-week time frame.
Each will receive two injections about a month apart in varying doses,
the National Institute of Allergy and Infectious Diseases says.
The study, which is a Phase I trial, is meant to establish that the
vaccine is safe and induces a desired response from participants’ immune
systems.
Proving that the vaccine is effective in preventing COVID-19 infection,
however, will require follow-up studies involving many more participants
– which will take many more months, experts say.
“Finding a safe and effective vaccine to prevent infection with [the
novel coronavirus] is an urgent public health priority,” NIAID Director
Dr Anthony Fauci said in a statement.
“This Phase I study, launched in record speed, is an important first step toward achieving that goal.”
The trial is funded by NIAID and run out of the Kaiser Permanente Washington Health Research Institute in Seattle.
The vaccine, which uses genetic material called messenger RNA, was
developed by NIAID scientists in collaboration with the biotech company
Moderna.
The agency has credited the speed with which it began a Phase I trial to
its prior studies on related coronaviruses SARS and MERS. Scientists
had previously worked on an experimental MERS vaccine targeting a
protein on the virus’ surface, which gave them a “head start for
developing a vaccine candidate to protect against COVID-19”, the
statement said.
Post Top Ad
Your Ad Spot
Subscribe to:
Post Comments (Atom)
Post Top Ad
Your Ad Spot
Tunde Ednut
Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat.
No comments:
Post a Comment